- Home
- Companies
- Finch Therapeutics Group, Inc.
- Products
- Finch - Model TAK-524 & FIN-525 - ...
Finch - Model TAK-524 & FIN-525 - Microbiome Therapeutics for Inflammatory Bowel Disease (IBD)
In collaboration with Takeda Pharmaceuticals, we are developing FIN-524 and FIN-525, orally administered, Targeted Consortia product candidates designed for the treatment of ulcerative colitis (UC) and Crohn’s disease (CD), respectively. UC and CD are the two most common types of IBD, an autoimmune condition that causes inflammation of the gastrointestinal (GI) tract.
The Unmet Need
3 million individuals in the US and 10 million individuals worldwide affected by IBD
Symptoms of IBD include severe, chronic abdominal pain, diarrhea, GI bleeding, weight loss, and fatigue
Today’s treatment options do not address the underlying causes of the disease and are ineffective for many individuals with IBD
FIN-524 & FIN-525 for IBD
Oral delivery of select bacterial strains grown in pure culture
Bacterial strain selection driven by data from human microbiota transplantation studies and mechanistic data
Strains target multiple potentially disease-modifying mechanisms
Being developed in partnership with Takeda, a global leader in GI disease